Brief: CelltrionShows Promising Results In Phase III Study Of Ct-P47, Biosimilar Candidate Of Roactemra In Patients With Rheumatoid Arthritis
13/06/2024 23:15
June 13 (Reuters) - Celltrion Inc 068270.KS :
* CELLTRION:SHOWS PROMISING RESULTS IN PHASE III STUDY OF
CT-P47,
BIOSIMILAR CANDIDATE OF ROACTEMRA IN PATIENTS WITH RHEUMATOID
ARTHRITIS AT EULAR 2024
* CELLTRION- CT-P47 HIGHLY SIMILAR IN TERMS OF EFFICACY &
SAFETY
TO REFERENCE PRODUCT ROACTEMRA FOR TREATMENT OF RHEUMATOID
ARTHRITIS UP TO WEEK 32
* CELLTRION INC -CT-P47 AI WAS WELL TOLERATED, AND NO NEW
SAFETY
SIGNALS WERE FOUND IN STUDY
Source text for Eikon: ID:nBw9J4pf2a
Further company coverage: 068270.KS
((Reutersbriefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion, Q3 Operating. Profit 510 Billion Won, Up 69% Y/Y
Brief: Celltrion, To Buy 100 Billion Won Worth Of Own Shares
Brief: Celltrion Sets Mid-To-Long Term Shareholder Return Target To One-Third Of Net Profit
South Korean chip stocks rally, tracking US AI gains; Temasek report adds support
Brief: Celltrion Q2 Operating Profit Rises 77.3% Y/Y To 430 Billion Won